Using Tumor Treating Fields for patients with pleural mesothelioma
TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study - TIGER Meso Study
This study is testing how well Tumor Treating Fields can help patients with pleural mesothelioma who are not candidates for surgery and are receiving regular treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 198 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | NovoCure Ltd. Industry-sponsored |
| Locations | 23 sites (Gauting, Bavaria and 22 other locations) |
| Trial ID | NCT05538806 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather real-world data on the effectiveness of Tumor Treating Fields (TTFields) in patients diagnosed with pleural mesothelioma who are receiving routine clinical care. Eligible patients will be those with histologically confirmed pleural mesothelioma who have no options for curative surgery and are planned to receive treatment with the NovoTTF-200T System. Participants will provide informed consent for their data to be used and processed for research purposes, allowing for a comprehensive analysis of TTFields in a clinical setting.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with histologically confirmed pleural mesothelioma and no curative treatment options.
Not a fit: Patients who have previously received NovoTTF-200T treatment for more than one week will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness of TTFields in improving outcomes for patients with pleural mesothelioma.
How similar studies have performed: While this approach is relatively novel in the context of pleural mesothelioma, previous studies on TTFields in other cancers have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥ 18 years of age * Histologically confirmed pleural mesothelioma without any option of curative resection * Planned treatment with NovoTTF-200T System according to IFU and medical guidelines * Life expectancy more than 3 months at day of enrollment * Signed informed consent for use and processing of data Exclusion Criteria: • Previous treatment with NovoTTF-200T for more than 1 week at day of enrollment
Where this trial is running
Gauting, Bavaria and 22 other locations
- Lungenklinik Gauting — Gauting, Bavaria, Germany (Recruiting)
- University Hospital Regensburg — Regensburg, Bavaria, Germany (Recruiting)
- Asklepios Klinikum Harburg — Harburg, Free and Hanseatic City of Hamburg, Germany (Recruiting)
- Klinikum Bremen-Ost — Bremen, Free Hanseatic City of Bremen, Germany (Recruiting)
- University Medicine Göttingen — Göttingen, Lower Saxony, Germany (Recruiting)
- University Hospital Carl Gustav Carus Dresden — Dresden, Saxony, Germany (Recruiting)
- Charité Universitätsmedizin Berlin — Berlin, Germany (Recruiting)
- Lungenklinik Heckeshorn — Berlin, Germany (Recruiting)
- Kliniken der Stadt Koeln — Cologne, Germany (Recruiting)
- Florence-Nightingale-Hospital — Düsseldorf, Germany (Recruiting)
- Klinikum Essen-Mitte — Essen, Germany (Recruiting)
- University Hospital Essen — Essen, Germany (Recruiting)
- Niels-Stensen Hospital — Georgsmarienhütte, Germany (Recruiting)
- Krankenhaus Martha-Maria Halle-Doelau — Halle, Germany (Recruiting)
- Medizinische Hochschule Hannover — Hanover, Germany (Recruiting)
- Lungenklinik Hemer — Hemer, Germany (Recruiting)
- Evangelisches Krankenhaus Herne — Herne, Germany (Recruiting)
- Krankenhaus Bethanien Moers — Moers, Germany (Recruiting)
- GEHO Muenster — Münster, Germany (Recruiting)
- Fachkliniken Wangen — Wangen, Germany (Recruiting)
- Azienda Ospedaliero-Universitaria di Alessandria "SS. Antonio e Biagio e C. Arrigo" — Alessandria, Italy (Recruiting)
- Humanitas Gavazzeni — Bergamo, Italy (Recruiting)
- Erasmus MC Cancer Centre — Rotterdam, Netherlands (Recruiting)
Study contacts
- Study coordinator: Giovanni Ceresoli
- Email: giovanni.ceresoli@mc.humanitas.it
- Phone: +392 9626717
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.